Compare Global X Artificial Intelligence & Technology ETF (AIQ) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Artificial Intelligence & Technology ETF vs Amphastar Pharmaceuticals Inc — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $63.23, while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: Global X Artificial Intelligence & Technology ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AIQ | AMPH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $30.81 |
52-Week Low | $43.88 | $16.87 |
Market Cap | — | $863.95M |
Enterprise Value | — | $1.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIQ trades at $63.35, up 2.26% with strong technical momentum as moving averages signal bullish sentiment. The ETF's systematic rebalancing approach provides diversified exposure to AI sector leaders. Recent news highlights AIQ's 25% gains while outperforming broader tech indices, positioning it well for the evolving AI investment landscape.
The outlook remains positive as AI infrastructure spending accelerates, though high RSI levels suggest potential near-term consolidation. Key risks include AI sector volatility and competitive ETF pressure, but institutional interest in thematic AI exposure supports long-term growth potential.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Artificial Intelligence & Technology ETF
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
